Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release)
SAN DIEGO, Nov. 21, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave® (naltrexone HCl / bupropion HCl extended release), in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and Drug Administration.
"A key component of Orexigen's strategy is to strengthen and extend intellectual property protection for Contrave," said Michael Narachi, CEO of Orexigen. "We are pleased that patent protection for use of this naltrexone formulation – and for Contrave – is now expected to extend at least to 2028."
